Compare BridgeBio Pharma Inc (BBIO) vs J M Smucker Co (SJM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs J M Smucker Co — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while J M Smucker Co trades at $108 (market cap $11.63B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and J M Smucker Co pays a 4.04% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SJM | |
|---|---|---|
Market Cap | $16.46B | $11.63B |
Sector | Health | Consumer Staples |
52-Week High | $90.17 | $117.05 |
52-Week Low | $44.81 | $89.53 |
Enterprise Value | $18.02B | $18.66B |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SJM trades at $110.53, down 0.96% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported mixed earnings with Q4 2026 beating estimates but Q3 2025 missing, alongside a net loss of $1.23 billion in 2025. Recent news highlights Uncrustables as a growth driver, while the Twinkie acquisition faces challenges. Cash flow improved to a net positive $7.90 million in 2025, though debt-to-asset ratio rose to 43.71%.
Outlook is cautious with analyst consensus at Buy (51.61%) and a $123.18 price target, but risks include high debt, margin pressure, and FY2027 sales guidance down 3-4%. The dividend yield of about 1% offers income, but growth depends on coffee margin recovery and Uncrustables expansion amid competitive headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →
